Earnings season will likely keep the tape jumpy this week, and the options market is already sketching out where the biggest ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

“2025 was an important year for Lilly. We reached millions more patients—launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval. We expanded our ...

Eli Lilly (LLY) ended the recent trading session at $1,146.90, demonstrating a -2.73% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the ...

Eli Lilly topped Novo in terms of both revenue and net income. Moderna’s stable financials were overshadowed by the regulatory whiplash it experienced in mid-February. Similarly, the vaccine segments ...

Eli Lilly (LLY) beat Q4 EPS estimates by 12%. Zepbound holds nearly 70% of new obesity prescriptions. Lilly CEO and 12 executives collectively purchased $104M in shares during February. Lilly expects ...

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be ...